Document Detail


Statin therapy in lupus-mediated atherogenesis: two birds with one stone?
MedLine Citation:
PMID:  21068103     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The atherosclerotic process is accelerated in patients with systemic lupus erythematosus (SLE). In addition to a robust lipid-lowering effect, various immunomodulatory functions have been ascribed to statins. By virtue of the latter they may be able to reduce atherosclerotic vascular disease in SLE by inhibiting immune activation within the arterial wall and by attenuating lupus activity. The effects of statins on SLE as well as on lupus-mediated atherogenesis in vivo are discussed in this viewpoint.
Authors:
Sander I van Leuven; Yanice V Mendez-Fernandez; Erik S Stroes; Paul P Tak; Amy S Major
Related Documents :
12607823 - Atherosclerosis, oxidation and endometriosis.
15586013 - Effect of c-reactive protein on vascular cells: evidence for a proinflammatory, proathe...
19436703 - Suppression of gata-3 nuclear import and phosphorylation: a novel mechanism of corticos...
Publication Detail:
Type:  Journal Article; Review     Date:  2010-11-10
Journal Detail:
Title:  Annals of the rheumatic diseases     Volume:  70     ISSN:  1468-2060     ISO Abbreviation:  Ann. Rheum. Dis.     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-01-14     Completed Date:  2011-02-17     Revised Date:  2012-03-21    
Medline Journal Info:
Nlm Unique ID:  0372355     Medline TA:  Ann Rheum Dis     Country:  England    
Other Details:
Languages:  eng     Pagination:  245-8     Citation Subset:  IM    
Affiliation:
Department of Vascular Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. s.i.vanleuven@amc.uva.nl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Atherosclerosis / etiology,  prevention & control*
Disease Models, Animal
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Lupus Erythematosus, Systemic / complications,  drug therapy*
Mice
Grant Support
ID/Acronym/Agency:
R01 HL088364-01A1/HL/NHLBI NIH HHS; R01 HL088364-02/HL/NHLBI NIH HHS; R01 HL088364-02S1/HL/NHLBI NIH HHS; R01 HL088364-03/HL/NHLBI NIH HHS; R01 HL088364-04/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Association of STAT3 and TNFRSF1A with ankylosing spondylitis in Han Chinese.
Next Document:  Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: explo...